Skip to main content
Home Clinical Trials

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

See what’s new.

Clinetic Announces Series A Funding Round Led by Sopris Capital

Clinetic is a medical records Duke start-up founded on technology developed by a team at the Duke Institute for Health Innovation

Read More

Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants

Tellus Therapeutics, a neonatal white matter injury therapeutics start-up, was co-founded by Dr. Eric Brenner (Pediatrics, SOM)

Read More

Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301

Evecxia Therapeutics is a Duke University start-up, founded by inventors Drs. Jacob Jacobsen and Marc Caron (Cell Biology, SOM) around their serotonin synthesis amplification therapeutic technology for mental health applications.

Read More

Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy

Istari Oncology was founded by Drs. Darell Bigner and Matthias Gromeier (Neurosurgery, SOM).

Read More

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Radius first licensed the indication for this drug discovered out of the Donald McDonnell lab from Duke in 2017.

Read More

Duke Leading Efforts to Develop Pan-Coronavirus Vaccine

  The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Duke Human Vaccine Institute (DHVI) $17.5 million in October 2021 to proceed with development of a next-generation “pan-coronavirus” vaccine, one that protects against…

Read More

Duke Institute Lands Federal Contract to Make Vaccine Candidates

Duke Health News, DURHAM, N.C., December 14, 2021 – The National Institute of Allergy and Infectious Diseases awarded researchers at the Duke Human Vaccine Institute a contract that enables it to compete for projects advancing investigational…

Read More

Adheris Health® and Improved Patient Outcomes, Inc. (IPO) Announce Strategic Partnership to Drive Positive Patient Health Outcomes

Delivering Behavioral-based Medication Adherence Solutions That Leverage Proven Behavior Change and Proprietary Duke University Evidence-Based Protocols BURLINGTON, MASS. AND RALEIGH, N.C. (PRWEB) OCTOBER 22, 2021 –Adheris Health, a MedAdvisor company, and leading provider of patient…

Read More

After Decades of Research, Drug Developed at Duke Receives FDA Approval

Dr. Louise Markert (left) with patient Jayla Turner in 2016.   By Sarah Avery DURHAM, N.C., October 11, 2021 – The phone rang into the pediatric unit that Louise Markert, M.D., Ph.D., was staffing as…

Read More